Skip to main content

Table 2 Ongoing adjuvant trials

From: Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)

Study

No. of patients

TNM stage

Therapy

Primary endpoint

US Intergroup E1609

1600

III (IIIB–c), IV (M1a, M1b)

Ipilimumab 3 mg/kg or 10 g/kg vs HD-IFN

RFS, OS

COMBI-AD

852

III (BRAF V600E/K)

Dabrafenib + trametinib vs. placebo

RFS

BRIM-8

725

IIC, III (BRAF V600; Cobas)

Vemurafenib vs. placebo

DFS

EORTC-1325/KEYNOTE-054

900

IIA (> 1 mm met), IIIb–C

Pembrolizumab vs. placebo

RFS, RFS in PDL1+

CheckMate-238

800

IIIB–C, IV

Nivolumab vs. ipilimumab 10 g/kg

RFS

US Intergroup S1404

1240

IIIA (N2), IIIB–C, M

Pembrolizumab vs. HD-IFN or ipilimumab 10 mg/kg

RFS, OS

C heckMate-915

1125

IIIB–D, IV

Ipilimumab + nivolumab vs ipilimumab or nivolumab

RFS